Glenmark Pharmaceuticals Ltd. (Glenmark) has received final approval by the United States Food & Drug Administration (U.S. FDA) for Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution, 0.2%|0.5%. Glenmark’s Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution, 0.2%|0.5% has been determined by the FDA to be bioequivalent and therapeutically equivalent to Combigan Ophthalmic Solution, 0.2%|0.5%, of AbbVie and will be distributed in the U.S. by Glenmark Pharmaceuticals, USA.
Glenmark`s Generic Brimonidine Tartrate;Timolol Receives Approval in the U.S.
Enforcement Report - Week of May 15, 2024
Enforcement Report - Week of June 7, 2023
Sentiss' Generic Timolol Maleate Receives Receives Approval in the U.S.
Enforcement Report - Week of January 25, 2023
Enforcement Report - Week of January 4, 2023
Upsher's Generic Brimonidine Tartrate and nTimolol Maleate Receives Approval in the U.S.
Akorn's Generic Brimonidine Tartrate,Timolol Maleate Receives Approval in the U.S.